Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02205333
Title A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Acronym MEDI6469
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors MedImmune LLC
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Research Site Scottsdale Arizona 85259 United States Details
Research Site Sacramento California 95817 United States Details
Research Site Santa Monica California 90404 United States Details
Research Site Washington, D.C. District of Columbia 20007 United States Details
Research Site Tampa Florida 33612 United States Details
Research Site Chicago Illinois 60611 United States Details
Research Site Detroit Michigan 48202 United States Details
Research Site Las Vegas Nevada 89169 United States Details
Research Site Hackensack New Jersey 7601 United States Details
Research Site Huntersville North Carolina 28078 United States Details
Research Site Portland Oregon 97213 United States Details
Research Site Memphis Tennessee 38120 United States Details
Research Site Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field